Trial Profile

A Phase 1b Study of REOLYSIN (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pelareorep (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Dexamethasone
Indications Multiple myeloma
Focus Adverse reactions; Proof of concept

Most Recent Events

05 Aug 2022 Planned End Date changed from 21 Feb 2023 to 21 Aug 2024.
05 Aug 2022 Planned primary completion date changed from 21 Feb 2022 to 21 Aug 2023.
08 Apr 2022 Results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com